Axon assisted a French VC company investing in a food tech start-up. We reviewed the target’s regulatory strategy under the EU novel foods framework, assessed its feasibility and outlined potential risks and how to mitigate these.
Updates
Explore our latest insights, regulatory updates, and strategic reports for the life sciences sector.
Type
Sectors
Expertises (3)
20 results
Newest first
Axon regularly acts as a sub-contractor for leading international firms to assist in regulatory due diligence in our fields of expertise: pharma, medical technology and food.
We have advised a company on defending itself against an enforcement action brought by the Netherlands Food and Consumer Product Safety Authority (NVWA).
One of our lawyers has acted as arbiter in international proceedings on MDR compliance.
We have conducted regulatory due diligence in connection with the acquisition of a pharmacy, covering compliance with applicable pharmaceutical and healthcare legislation.
We have conducted regulatory due diligence on behalf of a private equity firm in connection with the acquisition of a medical device manufacturer, covering MDR compliance (including notified body certificates and post-market surveillance obligations), as well as data protection aspects.
Axon regularly provides specialist due diligence support on a variety of corporate transactions in the life sciences sector.
We have assisted several clients in challenging tender decisions by Dutch hospitals.
Our firm is experienced in the conduct and defence of companies against freedom of information cases pertaining to confidential under Dutch and EU law, and has defended a number of companies, including a multinational, in a series of such cases over the years.
Our lawyers have acted as expert in national litigation cases on MDR compliance in other EU Member States.